U.S. pharma imports hit $200 billion in 2024, a 10% tariff could cost the sector $20 billion. Vertex and Alnylam are seen as most resilient to tariff, tax and Medicaid risks. With stocks plunging ...

The latest CNBC CFO Council Survey found that 60% of CFOs expect a U.S. recession later in 2025. Another 15% predict a recession next year. Ninety percent of the CFOs surveyed believe President ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

Granted permanent U.S. residence, as demonstrated by the issuance of a permanent residence card, i.e., a "Green Card" Granted U.S. citizenship Granted status as a "protected person" under 8 U.S.C.